Page 7 - Sharon Shacham News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Sharon shacham. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Sharon Shacham Today - Breaking & Trending Today

Karyopharm Therapeutics Inc (KPTI) Q1 2021 Earnings Call Transcript

Karyopharm Therapeutics Inc (KPTI) Q1 2021 Earnings Call Transcript
Motley Fool Transcribers
© The Motley Fool
Logo of jester cap with thought bubble.
Karyopharm Therapeutics Inc (NASDAQ: KPTI)
Popular Searches
Operator
Good morning. My name is Jason, and I ll be your conference operator today. At this time, I would like to welcome everyone to the Karyopharm Therapeutics First Quarter 2021 Financial Results Conference Call. There will be a question-and-answer session to follow. Please be advised that this call is being recorded at the Company s request.
I would now like to turn the call over to Mr. Ian Karp, Karyopharm s Senior Vice President, Investor and Public Relations.SPONSORED: ....

United States , Mike Mason , Paul Richardson , John Demaree , Arlinda Lee , Colleen Kusy Baird , Stephen Mitchener , David Lebowitz Morgan Stanley , Michael Kauffman , Peter Lawson , Arlinda Lee Canaccord , Michael Mason , Brian Abrahams , Red White , David Lebowitz , Maury Raycroft , Colleen Kusy , Ian Karp , Richard Paulson , Jonathan Chang , Sharon Shacham , Deric Joseph , Peter Lawson Barclays , Karyopharm Therapeutics Inc , Morgan Stanley , Motley Fool Karyopharm Therapeutics Inc ,

Karyopharm Announces the Appointment of Richard Paulson as President and Chief Executive Officer

Karyopharm Announces the Appointment of Richard Paulson as President and Chief Executive Officer
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United States , South Africa , Czech Republic , Ian Karp , Richard Paulson , Michaelg Kauffman , Barry Greene , Andrew Lee , Sharon Shacham , Company Scientific Advisory Board , Takeda Pharmaceutical Company , University Of Saskatchewan , University Of Toronto , Company As Senior Clinical Advisor , Pfizer Inc , Karyopharm Selective Inhibitor Of Nuclear Export , European Union , Karyopharm Therapeutics Inc , Drug Administration , European Commission , Prnewswire Karyopharm Therapeutics Inc , Exchange Commission , Corporate Governance Compliance Committee , Ipsen Pharmaceuticals Inc , Chief Executive Officer , Senior Clinical ,

Karyopharm Announces European Medicines Agency's Validation of its Type II Variation Marketing Authorization Application for NEXPOVIO®

Published: Apr 26, 2021

NEWTON, Mass., April 26, 2021 /PRNewswire/ Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the European Medicines Agency (EMA) has validated the Company s Type II Variation Marketing Authorization Application (MAA), which seeks to expand the currently authorized indication for NEXPOVIO® in the European Union to include, in combination with Velcade® (bortezomib) and low-dose dexamethasone, the treatment of adult patients with multiple myeloma who have received at least one prior therapy. Validation of the application confirms the submission is complete to begin the EMA s review process. The MAA is supported by the positive results from the pivotal Phase 3 BOSTON study, which evaluated once-weekly selinexor in combination with once-weekly Velcade® and low-dose dexamethasone (SVd) compared to standard twice-weekly Velcade® plus low-dose dexam ....

United States , Sharon Shacham , Selective Inhibitor Of Nuclear Export , Karyopharm Therapeutics Inc , World Health Organization , European Commission , Drug Administration , Takeda Pharmaceutical Company , Company Type Ii Variation Marketing Authorization Application , Prnewswire Karyopharm Therapeutics Inc , Exchange Commission , European Union , Karyopharm Selective Inhibitor Of Nuclear Export , European Medicines Agency , Committee For Medicinal Products Human Use , Marketing Authorization Application , Chief Scientific Officer , Medicinal Products , Human Use , Multiple Myeloma , Selective Inhibitor , Nuclear Export , Product Characteristics , Private Securities Litigation Reform Act , Annual Report , Karyopharm Therapeutics ,

Karyopharm Announces XPOVIO® (selinexor) Receives Regulatory Approval in Israel for the Treatment of Patients with Multiple Myeloma and Diffuse Large B-Cell Lymphoma

Share this article
Share this article
NEWTON, Mass., Feb. 4, 2021 /PRNewswire/ Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that its partner Promedico Ltd., a member of the Neopharm Group, has received a principal approval letter from the Israeli Ministry of Health, Israel s regulatory agency responsible for the approval of new medicines, granting the approval of XPOVIO® (selinexor) for the treatment of patients with either multiple myeloma or diffuse large B-cell lymphoma (DLBCL). The approved indications for XPOVIO are a) in combination with dexamethasone for the treatment of adult patients with relapsed refractory multiple myeloma who have received at least three prior therapies and whose disease is refractory to at least one proteasome inhibitor, at least one immunomodulatory agent, and an anti-CD38 monoclonal antibody, and b) for the treatment of adult patients with relapse ....

United States , Sharon Shacham , Selective Inhibitor Of Nuclear Export , Takeda Pharmaceutical Company , European Union , Karyopharm Selective Inhibitor Of Nuclear Export , Promedico Ltd , Information Department , Karyopharm Therapeutics Inc , Drug Administration , European Commission , Exchange Commission , Palestinian Authority , European Medicines Agency , Israeli Ministry Of Health , Neopharm Group , Karyopharm Therapeutics , Israeli Ministry , Medicinal Products , Human Use , Chief Scientific Officer , Selective Inhibitor , Nuclear Export , Marketing Authorization Application , New Drug Application , Medical Information ,

Karyopharm Receives Positive CHMP Opinion for NEXPOVIO® (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma

Karyopharm Receives Positive CHMP Opinion for NEXPOVIO® (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma
European Commission Decision Anticipated by April 2021
News provided by
Share this article
Share this article
NEWTON, Mass., Jan. 29, 2021 /PRNewswire/ Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the European Medicines Agency s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the conditional approval for NEXPOVIO® (selinexor) in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy. ....

United States , Sharon Shacham , Selective Inhibitor Of Nuclear Export , Karyopharm Therapeutics Inc , World Health Organization , European Commission , Drug Administration , Takeda Pharmaceutical Company , Exchange Commission , Karyopharm Selective Inhibitor Of Nuclear Export , European Union , European Medicines Agency , Committee For Medicinal Products Human Use , Information Department , Karyopharm Therapeutics , Medicinal Products , Human Use , European Economic Area , Chief Scientific Officer , New England Journal , Independent Review , Multiple Myeloma , Selective Inhibitor , Nuclear Export , Marketing Authorization Application , Medical Information ,